Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
2,298 results
  • Pharmacokinetics of Co-encapsulated Antiretrovirals with Ingestible Sensors. [Journal Article]
    AIDS Res Hum Retroviruses 2019Liu H, Daar ES, … Fletcher C
  • We investigated the use of a system with an ingestible sensor (Proteus Digital Health Feedback system) co-encapsulated with antiretrovirals (ARVs) to measure real-time adherence. To assess the safety and impact, if any, co-encapsulation might have on ARV concentrations, we evaluated the pharmacokinetics of ARVs co-encapsulated with an ingestible sensor for eight commonly used fixed-dose combinati…
  • HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia. [Journal Article]
    BMC Infect Dis 2019; 19(1):793Martínez Buitrago E, Oñate JM, … Rubiano LC
  • CONCLUSIONS: The overall prevalence of HLA-B*57:01 in Colombia was lower than the reported rates for other Latin American countries such as Brazil, Costa Rica, and Argentina, but similar in comparison to Chile and Mexico. The diversity in the racial and ethnic heritage shown in our data supports the recommendation to implement routine screening for the HLA-B*57:01 allele before initiation of abacavir-containing antiretroviral therapy in the Colombian HIV management guidelines.
  • Serum Levels of Fibroblast Growth Factor 23 in People Living with HIV. [Journal Article]
    Curr HIV Res 2019Yoshino Y, Seo K, … Ota Y
  • Fibroblast growth factor (FGF) 23 is a well-known phosphaturic hormone produced mainly by bone cells to maintain phosphate and mineral homeostasis. Serum FGF23 levels are elevated in patients with chronic kidney disease (CKD), and elevated FGF23 might increase the risk of cardiovascular disease (CVD). Several reports have documented an increased incidence of risk factors for osteopenia, CKD, and …
  • Abacavir-based Regimen for HIV-infected Children and Adolescents. [Journal Article]
    Indian Pediatr 2019; 56(8):685-686Pareek P, Singh DK, … Maurya M
  • We studied 48 children receiving abacavir-based HAART regimen, over a period of one-year for side effects and failure rates. None of the children developed hypersensitivity reaction. The CD4 count significantly improved from the time of enrolment till 12 months of therapy while the failure rate was 14.5%.
  • Multisystem impairment in South African adolescents with Perinatally acquired HIV on antiretroviral therapy (ART). [Journal Article]
    J Int AIDS Soc 2019; 22(8):e25386Frigati LJ, Brown K, … Zar HJ
  • CONCLUSIONS: Overall, 384 PHIV+ and 95 HIV- adolescents were included (mean age, 11.9 years; 49% female). Median age of ART initiation was 4.2 years (IQR: 1.7 to 7.6) and median CD4 count was 709 (IQR: 556 to 944) with 302 (79%) of PHIV+ adolescents virologically suppressed. Abacavir and Zidovudine were the most commonly used nucleoside reverse transcriptase inhibitors (NRTIs) with 60% of adolescents on non-nucleoside reverse transcriptase inhibitors (NNRTI) and 38% on a protease inhibitor (PI). Among PHIV+ adolescents, 167 (43.5%) had single system impairment only, 110 (28.6%) had two systems involved, and 39 (10.2%) had three or four systems involved. PHIV+ participants had more 2-system and 3-system impairment than HIV-, 110 (28.6%) versus 17 (17.9%), p = 0.03 and 39 (10.2%) versus 3 (4.3%), p = 0.03. PHIV+ participants who had failed a year of school (73.8% vs. 46.4%, p = 0.00) and with a viral load >1000 copies/mL at enrolment (16.8% vs. 8.1%, p = 0.03) were more likely to have dual or multisystem impairment. Of those with cardiac impairment, 86.7% had an additional system impaired. Similarly, in those with neurocognitive impairment, almost 60% had additional systems impaired and of those with respiratory impairment, 74% had additional systems impaired.Despite relatively early ART initiation, there is a substantial burden of multisystem chronic impairment among PHIV+ adolescents. This phenomenon needs to be further explored as this population ages and begins to engage in adult lifestyle factors that may compound these impairments.
New Search Next